Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of topical pazopanib eye drops in neovascular age-related macular degeneration
2008-002101-39Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in exudative macular degeneration, sponsored by GSK. Primary endpoint: Safety and tolerability. Started Jul 2008; status: completed.
02
Drugs
pazopanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2008-002101-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002101-39.